![]() |
|
|
Drug Metabolism and Pharmacokinetics Laboratory (M.K., K.M., H.K.,
A.O., K.K.), Chugai Pharmaceutical Co., Ltd.; and
Faculty of
Pharmaceutical Sciences (Y.K., Y.S.), University of Tokyo
We studied changes in the pharmacokinetics of
125I-recombinant human erythropoietin
(125I-rh-EPO) after repeated subcutaneous administration
once a week for 4 weeks. The plasma level of trichloroacetic
acid-precipitable radioactivity after the fourth administration of
125I-rh-EPO was minimal in 8 of 10 rats, whereas in the
other two rats, the plasma level was almost the same or somewhat higher than that in control rats that had received the vehicle solution 3 times instead of the first three sequential administrations. Antibody
against rh-EPO in serum was detected in all 10 rats receiving multiple
administrations of 125I-rh-EPO. However, the binding
capacity for 125I-rh-EPO in the latter two rats, assessed
by an in vitro serum binding study, was lower than for the
other eight rats, suggesting that the antibody level in these two was
lower. The effect of intravenous preinjection of various volumes of
anti-rh-EPO antiserum on the pharmacokinetics of
125I-rh-EPO was examined. The half-life in the
-phase
was prolonged at lower doses of antiserum. When the pretreatment dose
of antiserum was further increased, the half-life in the
-phase
rather shortened and the total body clearance
(CLtotal) increased. These results suggest that
repeated administration of rh-EPO induces the production of antibody
against rh-EPO that affects the pharmacokinetics of rh-EPO in a
biphasic manner; CLtotal was reduced when a
small amount of antibody was produced, and
CLtotal was increased when a large amount of
antibody was produced.
This article has been cited by other articles:
![]() |
A. R. Pachner Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis Arch Neurol, August 1, 2001; 58(8): 1299 - 1300. [Full Text] [PDF] |
||||